Risk factors
Compass Therapeutics (CMPX) risk factors
Item 1A of every Compass Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors80 risks2 dropped4 reworded
Compass Therapeutics shifted its public company status disclosure from emerging growth company to smaller reporting company, detailing specific revenue and non-affiliate share value thresholds.
Filed Mar 05, 2026 - FY2024 10-K risk factors82 risks
Compass Therapeutics is a clinical-stage biopharmaceutical company with an accumulated deficit of $365 million as of December 31, 2024. The company relies entirely on third-party contract manufacturing organizations and has never generated revenue from product sales.
Filed Feb 27, 2025